| Author | Phase | Tumor type | Line | Number of patients | Intervention | Randomised | SBRT to all disease + TKI | SBRT to liver mets | Remote disease | IFN | QoL | Toxicity | Comments |
|--------|-------|------------|------|-------------------|-------------|-----------|------------------------|-----------------|---------------|-----|-----|---------|----------|
| Wang et al. (2014) | III | NSCLC | 61 | 24 | After 1 line chemo and no PD | No previous EGFR inhibitor previous RT to local disease: exclusion criteria | 1 G3 AE in 15%; G3 cough in 3% | 6.1 m | II | 85% | 87% for BC | 25.0 m | SRRT | scored for all primary organs | II | 31% for BC | 1.7yr (range 0.3–8.9yr) for non-BC | T | 20.4 m | 24–60 Gy in 3# | 1-5 mets, ≤2 per organ, 1-3 liver mets (each max diameter 6 cm) Other disease NSCLC 1 G3 AE in 11%; G3 esophagitis in 15%; G3 cough in 3% | 41.6 m | SBRT to all disease (incl primary if agreed by PI) followed by SOC maint therapy |
| Wang et al. (2014) | III | NSCLC | 121 | 24 | After 1 line chemo and no PD | EGFRm NSCLC in 20% | 1 G3 AE (not due to SBRT) C: 2 G3 AE, 1 G4 AE | 8.4 m | II | 87% | 92% for LC | 38.8 m | NSCLC | 1.7yr (range 0.3–8.9yr) for non-BC | III | 87% | 92% for LC | 38.8 m | NSCLC | 1.7yr (range 0.3–8.9yr) for non-BC | T | 20.4 m | 24–60 Gy in 3# | 1-5 mets, ≤2 per organ, 1-3 liver mets (each max diameter 6 cm) Other disease NSCLC 1 G3 AE in 11%; G3 esophagitis in 15%; G3 cough in 3% | 41.6 m | SBRT to all disease (incl primary if agreed by PI) followed by SOC maint therapy |
| Wang et al. (2014) | III | NSCLC | 38 | 24 | After 1 line chemo and no PD | EGFRm NSCLC in 20% | 1 G3 AE (not due to SBRT) C: 2 G3 AE, 1 G4 AE | 8.4 m | II | 87% | 92% for LC | 38.8 m | NSCLC | 1.7yr (range 0.3–8.9yr) for non-BC | III | 87% | 92% for LC | 38.8 m | NSCLC | 1.7yr (range 0.3–8.9yr) for non-BC | T | 20.4 m | 24–60 Gy in 3# | 1-5 mets, ≤2 per organ, 1-3 liver mets (each max diameter 6 cm) Other disease NSCLC 1 G3 AE in 11%; G3 esophagitis in 15%; G3 cough in 3% | 41.6 m | SBRT to all disease (incl primary if agreed by PI) followed by SOC maint therapy |
| Wang et al. (2014) | III | NSCLC | 24 | 24 | After 1 line chemo and no PD | EGFRm NSCLC in 20% | 1 G3 AE (not due to SBRT) C: 2 G3 AE, 1 G4 AE | 8.4 m | II | 87% | 92% for LC | 38.8 m | NSCLC | 1.7yr (range 0.3–8.9yr) for non-BC | III | 87% | 92% for LC | 38.8 m | NSCLC | 1.7yr (range 0.3–8.9yr) for non-BC | T | 20.4 m | 24–60 Gy in 3# | 1-5 mets, ≤2 per organ, 1-3 liver mets (each max diameter 6 cm) Other disease NSCLC 1 G3 AE in 11%; G3 esophagitis in 15%; G3 cough in 3% | 41.6 m | SBRT to all disease (incl primary if agreed by PI) followed by SOC maint therapy |
| Wang et al. (2014) | III | NSCLC | 24 | 24 | After 1 line chemo and no PD | EGFRm NSCLC in 20% | 1 G3 AE (not due to SBRT) C: 2 G3 AE, 1 G4 AE | 8.4 m | II | 87% | 92% for LC | 38.8 m | NSCLC | 1.7yr (range 0.3–8.9yr) for non-BC | III | 87% | 92% for LC | 38.8 m | NSCLC | 1.7yr (range 0.3–8.9yr) for non-BC | T | 20.4 m | 24–60 Gy in 3# | 1-5 mets, ≤2 per organ, 1-3 liver mets (each max diameter 6 cm) Other disease NSCLC 1 G3 AE in 11%; G3 esophagitis in 15%; G3 cough in 3% | 41.6 m | SBRT to all disease (incl primary if agreed by PI) followed by SOC maint therapy |
| Wang et al. (2014) | III | NSCLC | 24 | 24 | After 1 line chemo and no PD | EGFRm NSCLC in 20% | 1 G3 AE (not due to SBRT) C: 2 G3 AE, 1 G4 AE | 8.4 m | II | 87% | 92% for LC | 38.8 m | NSCLC | 1.7yr (range 0.3–8.9yr) for non-BC | III | 87% | 92% for LC | 38.8 m | NSCLC | 1.7yr (range 0.3–8.9yr) for non-BC | T | 20.4 m | 24–60 Gy in 3# | 1-5 mets, ≤2 per organ, 1-3 liver mets (each max diameter 6 cm) Other disease NSCLC 1 G3 AE in 11%; G3 esophagitis in 15%; G3 cough in 3% | 41.6 m | SBRT to all disease (incl primary if agreed by PI) followed by SOC maint therapy |
| Wang et al. (2014) | III | NSCLC | 24 | 24 | After 1 line chemo and no PD | EGFRm NSCLC in 20% | 1 G3 AE (not due to SBRT) C: 2 G3 AE, 1 G4 AE | 8.4 m | II | 87% | 92% for LC | 38.8 m | NSCLC | 1.7yr (range 0.3–8.9yr) for non-BC | III | 87% | 92% for LC | 38.8 m | NSCLC | 1.7yr (range 0.3–8.9yr) for non-BC | T | 20.4 m | 24–60 Gy in 3# | 1-5 mets, ≤2 per organ, 1-3 liver mets (each max diameter 6 cm) Other disease NSCLC 1 G3 AE in 11%; G3 esophagitis in 15%; G3 cough in 3% | 41.6 m | SBRT to all disease (incl primary if agreed by PI) followed by SOC maint therapy |
| Wang et al. (2014) | III | NSCLC | 24 | 24 | After 1 line chemo and no PD | EGFRm NSCLC in 20% | 1 G3 AE (not due to SBRT) C: 2 G3 AE, 1 G4 AE | 8.4 m | II | 87% | 92% for LC | 38.8 m | NSCLC | 1.7yr (range 0.3–8.9yr) for non-BC | III | 87% | 92% for LC | 38.8 m | NSCLC | 1.7yr (range 0.3–8.9yr) for non-BC | T | 20.4 m | 24–60 Gy in 3# | 1-5 mets, ≤2 per organ, 1-3 liver mets (each max diameter 6 cm) Other disease NSCLC 1 G3 AE in 11%; G3 esophagitis in 15%; G3 cough in 3% | 41.6 m | SBRT to all disease (incl primary if agreed by PI) followed by SOC maint therapy |
| Wang et al. (2014) | III | NSCLC | 24 | 24 | After 1 line chemo and no PD | EGFRm NSCLC in 20% | 1 G3 AE (not due to SBRT) C: 2 G3 AE, 1 G4 AE | 8.4 m | II | 87% | 92% for LC | 38.8 m | NSCLC | 1.7yr (range 0.3–8.9yr) for non-BC | III | 87% | 92% for LC | 38.8 m | NSCLC | 1.7yr (range 0.3–8.9yr) for non-BC | T | 20.4 m | 24–60 Gy in 3# | 1-5 mets, ≤2 per organ, 1-3 liver mets (each max diameter 6 cm) Other disease NSCLC 1 G3 AE in 11%; G3 esophagitis in 15%; G3 cough in 3% | 41.6 m | SBRT to all disease (incl primary if agreed by PI) followed by SOC maint therapy |